{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T13:10:20Z","timestamp":1679231420884},"reference-count":72,"publisher":"Becaris Publishing Limited","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Compar. Effect. Res."],"published-print":{"date-parts":[[2015,5]]},"abstract":"<jats:p>\n            <jats:bold>Aim<\/jats:bold>\n            : Nine months of isoniazid (9INH) is the gold standard for treatment of latent tuberculosis infection (LTBI). This paper compares the effectiveness of 9 months of isoniazid with 4 months of transitional rifampin (9H4R) to alternative therapies, including 9INH, 6 months of isoniazid (6INH) and 6 months of isoniazid with 4 months of transitional rifampin (6H4R), for treatment of LTBI.\n            <jats:bold>Materials &amp; methods<\/jats:bold>\n            : Using an ethnically diverse clinic sample of 552 patients given treatment for LTBI with 9H4R, we use multilevel selection models to examine the adjusted comparative effectiveness of the regimens among ethnic groups that feature distinct genetic predispositions to side effects on INH. For unadjusted\/absolute effectiveness, we simulated cost\u2013effectiveness ratios for 4 months of rifampin (4RIF) and compared with bootstrapped confidence intervals for the alternative therapies.\n            <jats:bold>Results<\/jats:bold>\n            : There are variations in the comparative effectiveness across ethnic groups, with the most notable differences for 9H4R. For unadjusted\/absolute effectiveness, 4RIF presents the greatest net benefit for US born black and African patients. For all other ethnic groups, 6H4R was the most effective.\n            <jats:bold>Conclusion<\/jats:bold>\n            : Patient ethnicity affects tolerance to INH. 9H4R was the most effective LTBI treatment for all ethnicities. However, this result heavily depends on whether adjustments are made for self-selection.\n          <\/jats:p>","DOI":"10.2217\/cer.15.3","type":"journal-article","created":{"date-parts":[[2015,5,12]],"date-time":"2015-05-12T18:23:28Z","timestamp":1431455008000},"page":"239-257","source":"Crossref","is-referenced-by-count":1,"title":["A comparative effectiveness analysis of treatment for latent tuberculosis infection using multilevel selection models"],"prefix":"10.57264","volume":"4","author":[{"given":"Kyle R","family":"Fluegge","sequence":"first","affiliation":[{"name":"Department of Agricultural, Environmental &amp; Development Economics, Ohio State University, 2120 Fyffe Road, Columbus, OH 43210, USA"},{"name":"Division of Epidemiology, College of Public Health, Ohio State University, 2120 Fyffe Road, Columbus, OH 43210, USA"},{"name":"Institute for Health &amp; Environmental Research, Columbus, OH 43220, USA"},{"name":"Department of Epidemiology &amp; Biostatistics, Case Western Reserve University, 2103 Cornell Road, Cleveland, OH 44106, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian E","family":"Roe","sequence":"additional","affiliation":[{"name":"Department of Agricultural, Environmental &amp; Development Economics, Ohio State University, 2120 Fyffe Road, Columbus, OH 43210, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"key":"e_1_3_3_3_2","unstructured":"WHO\n                                . \n                                Global Tuberculosis Control 2011\n                                . \n                                WHO Geneva Switzerland\n                                 (\n                                2011\n                                ). \n                                http:\/\/whqlibdoc.who.int"},{"key":"e_1_3_3_4_2","unstructured":"CDC\n                                . \n                                Tuberculosis (TB)\n                                 (\n                                2012\n                                ). \n                                www.cdc.gov\/tb\/statistics\/default.htm"},{"issue":"20","key":"e_1_3_3_5_2","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1056\/NEJMsa031667","article-title":"Priorities for the treatment of latent tuberculosis infection in the United States","volume":"350","author":"Horsburgh CR","year":"2004","unstructured":"Horsburgh CR . Priorities for the treatment of latent tuberculosis infection in the United States . N. Engl. J. Med. 350 ( 20 ), 2060 \u2013 2067 ( 2004 ).","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"e_1_3_3_6_2","first-page":"555","article-title":"Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial","volume":"60","year":"1982","unstructured":"Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial . Bull. World Health Organ. 60 ( 4 ), 555 \u2013 564 ( 1982 ).","journal-title":"Bull. World Health Organ."},{"issue":"4","key":"e_1_3_3_7_2","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1164\/rccm.200404-478OC","article-title":"Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months","volume":"170","author":"Menzies D","year":"2004","unstructured":"Menzies D , Dion MJ , Rabinovitch B Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months . Am. J. Respir. Crit. Care Med. 170 ( 4 ), 445 \u2013 449 ( 2004 ).","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"11","key":"e_1_3_3_8_2","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1164\/rccm.200901-0153OC","article-title":"Costs and cost\u2013effectiveness of four treatment regimens for latent tuberculosis infection","volume":"179","author":"Holland DP","year":"2009","unstructured":"Holland DP , Sanders GD , Hamilton CD Costs and cost\u2013effectiveness of four treatment regimens for latent tuberculosis infection . Am. J. Respir. Crit. Care Med. 179 ( 11 ), 1055 \u2013 1060 ( 2009 ).","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"12","key":"e_1_3_3_9_2","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1086\/647944","article-title":"4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity","volume":"49","author":"Ziakas PD","year":"2009","unstructured":"Ziakas PD , Mylonakis E . 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity . Clin. Infect. Dis. 49 ( 12 ), 1883 \u2013 1889 ( 2009 ).","journal-title":"Clin. Infect. Dis."},{"issue":"7","key":"e_1_3_3_10_2","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1136\/thx.2009.125054","article-title":"Impact of treatment completion, intolerance and adverse events on health system costs in a randomized trial of 4 months rifampin or 9 months isoniazid for latent TB","volume":"65","author":"Aspler A","year":"2010","unstructured":"Aspler A , Long R , Trajman A Impact of treatment completion, intolerance and adverse events on health system costs in a randomized trial of 4 months rifampin or 9 months isoniazid for latent TB . Thorax 65 ( 7 ), 582 \u2013 587 ( 2010 ).","journal-title":"Thorax"},{"issue":"3","key":"e_1_3_3_11_2","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1086\/600394","article-title":"A retrospective evaluation of completion rates, total cost, and adverse effects for treatment of latent tuberculosis infection in a public health clinic in central Massachusetts","volume":"49","author":"Young H","year":"2009","unstructured":"Young H , Wessolossky M , Ellis J A retrospective evaluation of completion rates, total cost, and adverse effects for treatment of latent tuberculosis infection in a public health clinic in central Massachusetts . Clin. Infect. Dis. 49 ( 3 ), 424 \u2013 427 ( 2009 ).","journal-title":"Clin. Infect. Dis."},{"issue":"4","key":"e_1_3_3_12_2","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/aepp\/ppq023","article-title":"The power and pitfalls of experiments in development economics: some non-random reflections","volume":"32","author":"Barrett CB","year":"2010","unstructured":"Barrett CB , Carter MR . The power and pitfalls of experiments in development economics: some non-random reflections . Appl. Econ. Perspect. Policy 32 ( 4 ), 515 \u2013 548 ( 2010 ).","journal-title":"Appl. Econ. Perspect. Policy"},{"issue":"6","key":"e_1_3_3_13_2","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1097\/MLR.0b013e3181d57473","article-title":"Practice based evidence: incorporating clinical heterogeneity and patient-reported outcomes for comparative effectiveness research","volume":"48","author":"Horn SD","year":"2010","unstructured":"Horn SD , Gassaway J . Practice based evidence: incorporating clinical heterogeneity and patient-reported outcomes for comparative effectiveness research . Med. Care 48 ( 6 ), S17 \u2013 S22 ( 2010 ).","journal-title":"Med. Care"},{"key":"e_1_3_3_14_2","unstructured":"Ip\n                                        S Paulus\n                                        JK Balk\n                                        EM\n                                Role of single group studies in Agency for Healthcare Research and Quality comparative effectiveness reviews. Agency for Healthcare Research and Quality\n                                 (\n                                2013\n                                ). \n                                www.effectivehealthcare.ahrq.gov"},{"issue":"2","key":"e_1_3_3_15_2","first-page":"265","article-title":"Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist?","volume":"60","author":"Nebert DW","year":"1997","unstructured":"Nebert DW . Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist? Am. J. Hum. Genet. 60 ( 2 ), 265 \u2013 271 ( 1997 ).","journal-title":"Am. J. Hum. Genet."},{"issue":"4","key":"e_1_3_3_16_2","first-page":"203","article-title":"Genetic polymorphisms, drug metabolism and drug concentrations","volume":"25","author":"Shenfi GM","year":"2004","unstructured":"Shenfi GM . Genetic polymorphisms, drug metabolism and drug concentrations . Clin. Biochem. Rev. 25 ( 4 ), 203 \u2013 206 ( 2004 ).","journal-title":"Clin. Biochem. Rev."},{"issue":"6","key":"e_1_3_3_17_2","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/00008571-199712000-00009","article-title":"Meta-analysis of phenotype and genotype of NAT2 deficiency in Chinese populations","volume":"7","author":"Xie HG","year":"1997","unstructured":"Xie HG , Xu ZH , Ou-Yang DS Meta-analysis of phenotype and genotype of NAT2 deficiency in Chinese populations . Pharmacogenetics 7 ( 6 ), 503 \u2013 514 ( 1997 ).","journal-title":"Pharmacogenetics"},{"issue":"2","key":"e_1_3_3_18_2","doi-asserted-by":"crossref","first-page":"R23","DOI":"10.1186\/ar2134","article-title":"Association of the diplotype configuration at the N-acetyltransferase 2 gene with adverse events with co-trimoxazole in Japanese patients with systemic lupus erythematosus","volume":"9","author":"Soejima M","year":"2007","unstructured":"Soejima M , Sugiura T , Kawaguchi Y Association of the diplotype configuration at the N-acetyltransferase 2 gene with adverse events with co-trimoxazole in Japanese patients with systemic lupus erythematosus . Arthritis Res. Ther. 9 ( 2 ), R23 ( 2007 ).","journal-title":"Arthritis Res. Ther."},{"issue":"5","key":"e_1_3_3_19_2","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/jep.12204","article-title":"Assessing the impact of patient self-selection on the costs to treat latent tuberculosis infection (LTBI) with isoniazid and transitional rifampin","volume":"20","author":"Fluegge KR","year":"2014","unstructured":"Fluegge KR . Assessing the impact of patient self-selection on the costs to treat latent tuberculosis infection (LTBI) with isoniazid and transitional rifampin . J. Eval. Clin. Pract. 20 ( 5 ), 685 \u2013 691 ( 2014 ).","journal-title":"J. Eval. Clin. Pract."},{"issue":"19","key":"e_1_3_3_20_2","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMp0901355","article-title":"Does comparative-effectiveness research threaten personalized medicine?","volume":"360","author":"Garber AM","year":"2009","unstructured":"Garber AM , Tunis SR . Does comparative-effectiveness research threaten personalized medicine? N. Engl. J. Med. 360 ( 19 ), 1925 \u2013 1927 ( 2009 ).","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"e_1_3_3_21_2","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1377\/hlthaff.2010.0642","article-title":"Comparative effectiveness and personalized medicine: evolving together or apart?","volume":"29","author":"Epstein R","year":"2010","unstructured":"Epstein R , Teagarden JR . Comparative effectiveness and personalized medicine: evolving together or apart? Health Affairs 29 ( 10 ), 1783 \u2013 1787 ( 2010 ).","journal-title":"Health Affairs"},{"issue":"10","key":"e_1_3_3_22_2","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/GIM.0b013e3181b99b90","article-title":"Comparative effectiveness research and genomic medicine: an evolving partnership for 21st century medicine","volume":"11","author":"Khoury MJ","year":"2009","unstructured":"Khoury MJ , Rich EC , Randhawa G Comparative effectiveness research and genomic medicine: an evolving partnership for 21st century medicine . Genet. Med. 11 ( 10 ), 707 \u2013 711 ( 2009 ).","journal-title":"Genet. Med."},{"issue":"12","key":"e_1_3_3_23_2","doi-asserted-by":"crossref","first-page":"5237","DOI":"10.1073\/pnas.88.12.5237","article-title":"Molecular mechanism of slow acetylation of drugs and carcinogens in humans","volume":"88","author":"Blum M","year":"1991","unstructured":"Blum M , Demierre A , Grant DM Molecular mechanism of slow acetylation of drugs and carcinogens in humans . Proc. Natl Acad. Sci. USA 88 ( 12 ), 5237 \u2013 5241 ( 1991 ).","journal-title":"Proc. Natl Acad. Sci. USA"},{"issue":"6","key":"e_1_3_3_24_2","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00228-006-0111-5","article-title":"CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis","volume":"62","author":"Vuilleumier N","year":"2006","unstructured":"Vuilleumier N , Rossier MF , Chiappe A CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis . Eur. J. Clin. Pharmacol. 62 ( 6 ), 423 \u2013 429 ( 2006 ).","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"3","key":"e_1_3_3_25_2","first-page":"581","article-title":"Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity","volume":"57","author":"Cascorbi I","year":"1995","unstructured":"Cascorbi I , Drakoulis N , Brockmoller J Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity . Am. J. Hum. Genet. 57 ( 3 ), 581 \u2013 592 ( 1995 ).","journal-title":"Am. J. Hum. Genet."},{"issue":"5","key":"e_1_3_3_26_2","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/BF02353477","article-title":"N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism","volume":"24","author":"Spielberg SP","year":"1996","unstructured":"Spielberg SP . N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism . J. Pharmacokinet. Biopharm. 24 ( 5 ), 509 \u2013 519 ( 1996 ).","journal-title":"J. Pharmacokinet. Biopharm."},{"issue":"5","key":"e_1_3_3_27_2","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s00228-012-1429-9","article-title":"NAT2 genotype guided regimen reduces isoniazid- induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy","volume":"69","author":"Azuma J","year":"2013","unstructured":"Azuma J , Ohno M , Kubota R NAT2 genotype guided regimen reduces isoniazid- induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy . Eur. J. Clin. Pharmacol. 69 ( 5 ), 1091 \u2013 1101 ( 2013 ).","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"3","key":"e_1_3_3_28_2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00004836-198109000-00012","article-title":"Risk factors for isoniazid (INH)-induced liver dysfunction","volume":"3","author":"Dickinson DS","year":"1981","unstructured":"Dickinson DS , Bailey WC , Hirschowitz BI Risk factors for isoniazid (INH)-induced liver dysfunction . J. Clin. Gastroenterol. 3 ( 3 ), 271 \u2013 279 ( 1981 ).","journal-title":"J. Clin. Gastroenterol."},{"issue":"2","key":"e_1_3_3_29_2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/hep.1840060223","article-title":"Elevated serum aminotransferase induced by isoniazid in relation to isoniazid acetylator phenotype","volume":"6","author":"Yamamoto T","year":"1986","unstructured":"Yamamoto T , Suou T , Hirayama C . Elevated serum aminotransferase induced by isoniazid in relation to isoniazid acetylator phenotype . Hepatology 6 ( 2 ), 295 \u2013 298 ( 1986 ).","journal-title":"Hepatology"},{"issue":"10","key":"e_1_3_3_30_2","first-page":"420","article-title":"Acetylator phenotype in patients with allergic diseases and its clinical significance","volume":"28","author":"Orzechowska-Juzwenko K","year":"1990","unstructured":"Orzechowska-Juzwenko K , Milejski P , Patkowski J Acetylator phenotype in patients with allergic diseases and its clinical significance . Int. J. Clin. Pharmacol. Ther. Toxicol. 28 ( 10 ), 420 \u2013 425 ( 1990 ).","journal-title":"Int. J. Clin. Pharmacol. Ther. Toxicol."},{"issue":"5","key":"e_1_3_3_31_2","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/S0009-9236(99)70076-7","article-title":"Relationship between acetylation polymorphism and risk of atopic diseases","volume":"65","author":"Gawronska-Szklarz B","year":"1999","unstructured":"Gawronska-Szklarz B Relationship between acetylation polymorphism and risk of atopic diseases . Clin. Pharmacol. Ther. 65 ( 5 ), 562 \u2013 569 ( 1999 ).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"e_1_3_3_32_2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1134\/S0026893309010087","article-title":"Association of NAT2 polymorphisms with susceptibility to psoriasis in the Moscow population","volume":"43","author":"Kozhekbaeva ZM","year":"2009","unstructured":"Kozhekbaeva ZM , Gra OA , Fadeev VS Association of NAT2 polymorphisms with susceptibility to psoriasis in the Moscow population . Mol. Biol. (Mosk). 43 ( 1 ), 55 \u2013 67 ( 2009 ).","journal-title":"Mol. Biol. (Mosk)."},{"issue":"1","key":"e_1_3_3_33_2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1158\/1055-9965.EPI-05-0618","article-title":"Effect of NAT1 and NAT2 genetic polymorphisms on colorectal cancer risk associated with exposure to tobacco smoke and meat consumption","volume":"15","author":"Lilla C","year":"2006","unstructured":"Lilla C , Verla-Tebit E , Risch A Effect of NAT1 and NAT2 genetic polymorphisms on colorectal cancer risk associated with exposure to tobacco smoke and meat consumption . Cancer Epidemiol. Biomarkers Prev. 15 ( 1 ), 99 \u2013 107 ( 2006 ).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"3","key":"e_1_3_3_34_2","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s10549-010-0807-1","article-title":"NAT2 polymorphisms combining with smoking associated with breast cancer susceptibility: a meta-analysis","volume":"123","author":"Zhang J","year":"2010","unstructured":"Zhang J , Qiu L , Wang Z NAT2 polymorphisms combining with smoking associated with breast cancer susceptibility: a meta-analysis . Breast Cancer Res. Treat. 123 ( 3 ), 877 \u2013 883 ( 2010 ).","journal-title":"Breast Cancer Res. Treat."},{"issue":"9","key":"e_1_3_3_35_2","first-page":"3683","article-title":"Association of slow acetylation profile of NAT2 with breast and gastric cancer risk in Brazil","volume":"33","author":"Fernandes MR","year":"2013","unstructured":"Fernandes MR , De Carvalho DC , Dos Santos A Association of slow acetylation profile of NAT2 with breast and gastric cancer risk in Brazil . Anticancer Res. 33 ( 9 ), 3683 \u2013 3689 ( 2013 ).","journal-title":"Anticancer Res."},{"key":"e_1_3_3_36_2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev.publhealth.012809.103532","article-title":"The behavioral response to personalized genetic information: will genetic risk profiles motivate individuals and families to choose more healthful behaviors?","volume":"31","author":"McBride CM","year":"2010","unstructured":"McBride CM , Koehly LM , Sanderson SC The behavioral response to personalized genetic information: will genetic risk profiles motivate individuals and families to choose more healthful behaviors? Annu. Rev. Public Health 31 , 89 \u2013 103 ( 2010 ).","journal-title":"Annu. Rev. Public Health"},{"issue":"1","key":"e_1_3_3_37_2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1207\/s15324796abm3301_3","article-title":"Does genetic testing result in behavioral health change? Changes in smoking behavior following testing for alpha-1 antitrypsin deficiency","volume":"33","author":"Carpenter MJ","year":"2007","unstructured":"Carpenter MJ , Strange C , Jones Y Does genetic testing result in behavioral health change? Changes in smoking behavior following testing for alpha-1 antitrypsin deficiency . Ann. Behav. Med. 33 ( 1 ), 22 \u2013 28 ( 2007 ).","journal-title":"Ann. Behav. Med."},{"issue":"1","key":"e_1_3_3_38_2","first-page":"99","article-title":"Effect of NAT1 and NAT2 genetic polymorphisms on colorectal cancer risk associatedwith exposure to tobacco smoke and meat consumption.","volume":"15","author":"Lilla C","year":"2006","unstructured":"Lilla C , Verla-Tebit E , Risch A Effect of NAT1 and NAT2 genetic polymorphisms on colorectal cancer risk associatedwith exposure to tobacco smoke and meat consumption. . Cancer EpidemiologyBiomarkers & Prevention 15 ( 1 ), 99 \u2013 107 ( 2006 ).","journal-title":"Cancer EpidemiologyBiomarkers & Prevention"},{"issue":"3","key":"e_1_3_3_39_2","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1164\/rccm.200701-057OC","article-title":"Prevalence of tuberculosis infection in the United States population","volume":"177","author":"Bennett DE","year":"2008","unstructured":"Bennett DE , Courval JM , Onorato I Prevalence of tuberculosis infection in the United States population . Am. J. Respir. Crit. Care Med. 177 ( 3 ), 348 \u2013 355 ( 2008 ).","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"12","key":"e_1_3_3_40_2","first-page":"1","article-title":"Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America","volume":"54","author":"Taylor Z","year":"2005","unstructured":"Taylor Z , Nolan CM , Blumberg HM Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America . Morb. Mortal. Wkly Rep. 54 ( RR12 ), 1 \u2013 81 ( 2005 ).","journal-title":"Morb. Mortal. Wkly Rep."},{"issue":"4","key":"e_1_3_3_41_2","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1164\/rccm.200706-950OC","article-title":"Tuberculosis Infection in the United States","volume":"177","author":"Khan K","year":"2008","unstructured":"Khan K , Wang J , Hu W Tuberculosis Infection in the United States . Am. J. Respir. Crit. Care Med. 177 ( 4 ), 455 \u2013 460 ( 2008 ).","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"6","key":"e_1_3_3_42_2","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.jhep.2005.06.008","article-title":"Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease","volume":"43","author":"Suzuki A","year":"2005","unstructured":"Suzuki A , Lindor K , Saver J Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease . J. Hepatol. 43 ( 6 ), 1060 \u2013 1066 ( 2005 ).","journal-title":"J. Hepatol."},{"issue":"4","key":"e_1_3_3_43_2","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ypmed.2011.08.028","article-title":"Multiple health behaviors and serum hepatic enzymes among US adults with obesity","volume":"53","author":"Tsai J","year":"2011","unstructured":"Tsai J , Ford ES , Zhao G Multiple health behaviors and serum hepatic enzymes among US adults with obesity . Prev. Med. 53 ( 4 ), 278 \u2013 283 ( 2011 ).","journal-title":"Prev. Med."},{"issue":"1","key":"e_1_3_3_44_2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1053\/j.gastro.2004.09.075","article-title":"Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States","volume":"128","author":"Ruhl CE","year":"2005","unstructured":"Ruhl CE , Everhart JE . Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States . Gastroenterology 128 ( 1 ), 24 \u2013 32 ( 2005 ).","journal-title":"Gastroenterology"},{"issue":"7","key":"e_1_3_3_45_2","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/oxfordjournals.aje.a009315","article-title":"Association between diabetes and elevated serum alanine aminotransferase activity among Mexican Americans","volume":"146","author":"Meltzer AA","year":"1997","unstructured":"Meltzer AA , Everhart JE . Association between diabetes and elevated serum alanine aminotransferase activity among Mexican Americans . Am. J. Epidemiol. 146 ( 7 ), 565 \u2013 571 ( 1997 ).","journal-title":"Am. J. Epidemiol."},{"issue":"1","key":"e_1_3_3_46_2","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s12072-011-9309-4","article-title":"Comparison between acetylator phenotype and genotype polymorphism of N-acetyltransferase-2 in tuberculosis patients","volume":"6","author":"Rana SV","year":"2012","unstructured":"Rana SV , Ola RP , Sharma SK Comparison between acetylator phenotype and genotype polymorphism of N-acetyltransferase-2 in tuberculosis patients . Hepatol. Int. 6 ( 1 ), 397 \u2013 402 ( 2012 ).","journal-title":"Hepatol. Int."},{"issue":"4","key":"e_1_3_3_47_2","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1053\/jhep.2002.32102","article-title":"Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for anti-tuberculosis drug-induced hepatitis","volume":"35","author":"Huang YS","year":"2002","unstructured":"Huang YS , Chern HD , Su WJ Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for anti-tuberculosis drug-induced hepatitis . Hepatology 35 ( 4 ), 883 \u2013 889 ( 2002 ).","journal-title":"Hepatology"},{"issue":"2","key":"e_1_3_3_48_2","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1128\/AAC.05037-11","article-title":"Influence of NAT2 polymorphisms on sulfamethoxazole pharmacokinetics in renal transplant recipients","volume":"56","author":"Kagaya H","year":"2012","unstructured":"Kagaya H , Miura M , Niioka T Influence of NAT2 polymorphisms on sulfamethoxazole pharmacokinetics in renal transplant recipients . Antimicrob. Agents Chemother. 56 ( 2 ), 825 \u2013 829 ( 2012 ).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"e_1_3_3_49_2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0304-4076(93)90106-F","article-title":"Simultaneous equations for hazards: Marriage duration and fertility timing","volume":"56","author":"Lillard LA","year":"1993","unstructured":"Lillard LA . Simultaneous equations for hazards: Marriage duration and fertility timing . J. Econom. 56 ( 1 ), 189 \u2013 217 ( 1993 ).","journal-title":"J. Econom."},{"issue":"1","key":"e_1_3_3_50_2","first-page":"13","article-title":"The generalized Gompertz distribution","volume":"37","author":"El-Gohary A","year":"2011","unstructured":"El-Gohary A , Alshamrani A , Al-Otaibi AN . The generalized Gompertz distribution . Appl. Math. Model. 37 ( 1\u20132 ), 13 \u2013 24 ( 2011 ).","journal-title":"Appl. Math. Model."},{"issue":"6","key":"e_1_3_3_51_2","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1378\/chest.130.6.1712","article-title":"Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin","volume":"130","author":"Lardizabal A","year":"2006","unstructured":"Lardizabal A , Passannante M , Kojakali F Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin . Chest 130 ( 6 ), 1712 \u2013 1717 ( 2006 ).","journal-title":"Chest"},{"issue":"17","key":"e_1_3_3_52_2","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1001\/archinte.166.17.1863","article-title":"Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study","volume":"166","author":"Page KR","year":"2006","unstructured":"Page KR , Sifakis F , Montes de Oca R Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study . Arch. Intern. Med. 166 ( 17 ), 1863 \u2013 1870 ( 2006 ).","journal-title":"Arch. Intern. Med."},{"issue":"1","key":"e_1_3_3_53_2","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1186\/1471-2458-12-454","article-title":"Effect of scheduled monitoring of liver function during anti-tuberculosis treatment in a retrospective cohort in China","volume":"12","author":"Wu S","year":"2012","unstructured":"Wu S , Xia Y , Lv X Effect of scheduled monitoring of liver function during anti-tuberculosis treatment in a retrospective cohort in China . BMC Public Health 12 ( 1 ), 454 \u2013 460 ( 2012 ).","journal-title":"BMC Public Health"},{"issue":"5","key":"e_1_3_3_54_2","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/hec.678","article-title":"Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost\u2013effectiveness analysis","volume":"11","author":"Hoch JS","year":"2002","unstructured":"Hoch JS , Briggs AH , Willan AR . Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost\u2013effectiveness analysis . Health Econ. 11 ( 5 ), 415 \u2013 430 ( 2002 ).","journal-title":"Health Econ."},{"key":"e_1_3_3_55_2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2307\/1912352","article-title":"Sample selection bias as a specification error","volume":"47","author":"Heckman JJ","year":"1979","unstructured":"Heckman JJ . Sample selection bias as a specification error . Econometrica 47 , 153 \u2013 161 ( 1979 ).","journal-title":"Econometrica"},{"key":"e_1_3_3_56_2","article-title":"Using spatial disease patterns and patient-level characteristics to describe prevalence elastic behavior in treatment for latent tuberculosis infection (LTBI)","author":"Fluegge K","year":"2015","unstructured":"Fluegge K . Using spatial disease patterns and patient-level characteristics to describe prevalence elastic behavior in treatment for latent tuberculosis infection (LTBI) . Public Health Nurs. doi:10.1111\/phn.12170 ( 2015 ) ( In Press ).","journal-title":"Public Health Nurs."},{"issue":"3","key":"e_1_3_3_57_2","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2307\/1912157","article-title":"Distribution-free maximum likelihood estimator of the binary choice model","volume":"51","author":"Cosslett SR","year":"1983","unstructured":"Cosslett SR . Distribution-free maximum likelihood estimator of the binary choice model . Econometrica 51 ( 3 ), 765 \u2013 782 ( 1983 ).","journal-title":"Econometrica"},{"key":"e_1_3_3_58_2","volume-title":"Stata Statistical Software: Release 11.","author":"StataCorp","year":"2009","unstructured":"StataCorp . Stata Statistical Software: Release 11. College Station, StataCorp LP , TX, USA ( 2009 )."},{"key":"e_1_3_3_59_2","volume-title":"aML Multilevel Multiprocess Statistical Software.","author":"Lillard LA","year":"2003","unstructured":"Lillard LA , Constantijn DR . aML Multilevel Multiprocess Statistical Software. Econ-Ware , Los Angeles, CA, USA ( 2003 ). www.applied-ml.com"},{"issue":"3","key":"e_1_3_3_60_2","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/(SICI)1099-1050(199705)6:3<243::AID-HEC269>3.0.CO;2-Z","article-title":"Confidence intervals for cost\u2013effectiveness ratios: a comparison of four methods","volume":"6","author":"Polsky D","year":"1997","unstructured":"Polsky D , Glick HA , Willke R Confidence intervals for cost\u2013effectiveness ratios: a comparison of four methods . Health Econ. 6 ( 3 ), 243 \u2013 252 ( 1997 ).","journal-title":"Health Econ."},{"issue":"6","key":"e_1_3_3_61_2","first-page":"1","article-title":"Targeted tuberculin testing and treatment of latent tuberculosis infection","volume":"49","author":"Cohn DL","year":"2000","unstructured":"Cohn DL , O'Brien RJ , Geiter LJ Targeted tuberculin testing and treatment of latent tuberculosis infection . Morb. Mortal. Wkly Rep. 49 ( 6 ), 1 \u2013 54 ( 2000 ).","journal-title":"Morb. Mortal. Wkly Rep."},{"issue":"4","key":"e_1_3_3_62_2","first-page":"555","article-title":"Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial (International Union against Tuberculosis) Committee on Prophylaxis","volume":"60","author":"Thompson NJ","year":"1982","unstructured":"Thompson NJ . Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial (International Union against Tuberculosis) Committee on Prophylaxis . Bull. World Health Organ. 60 ( 4 ), 555 \u2013 564 ( 1982 ).","journal-title":"Bull. World Health Organ."},{"key":"e_1_3_3_63_2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1164\/ajrccm\/145.1.36","article-title":"A double-blind placebo-controlled clinical trial of three anti-tuberculosis chemo-prophylaxis regimens in patients with silicosis in Hong Kong","volume":"145","author":"Girling DJ","year":"1992","unstructured":"Girling DJ , Chan SL . A double-blind placebo-controlled clinical trial of three anti-tuberculosis chemo-prophylaxis regimens in patients with silicosis in Hong Kong . Am. Rev. Resp. Dis. 145 , 36 \u2013 41 ( 1992 ).","journal-title":"Am. Rev. Resp. Dis."},{"issue":"1","key":"e_1_3_3_64_2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0738-3991(02)00268-9","article-title":"Somatic complaints and isoniazid (INH) side effects in Latino adolescents with latent tuberculosis infection (LTBI)","volume":"52","author":"Berg J","year":"2004","unstructured":"Berg J , Blumberg EJ , Sipan CL Somatic complaints and isoniazid (INH) side effects in Latino adolescents with latent tuberculosis infection (LTBI) . Patient Educ. Couns. 52 ( 1 ), 31 \u2013 39 ( 2004 ).","journal-title":"Patient Educ. Couns."},{"issue":"4","key":"e_1_3_3_65_2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1164\/rccm.200303-390OC","article-title":"Use of isoniazid for latent tuberculosis infection in a public health clinic","volume":"168","author":"LoBue PA","year":"2003","unstructured":"LoBue PA , Moser KS . Use of isoniazid for latent tuberculosis infection in a public health clinic . Am. J. Respir. Crit. Care Med. 168 ( 4 ), 443 \u2013 447 ( 2003 ).","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"8","key":"e_1_3_3_66_2","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0277-9536(02)00176-4","article-title":"Predictors of adherence to treatment for latent tuberculosis infection in high-risk Latino adolescents: a behavioral epidemiological analysis","volume":"56","author":"Hovell M","year":"2003","unstructured":"Hovell M , Blumberg E , Gil-Trejo L Predictors of adherence to treatment for latent tuberculosis infection in high-risk Latino adolescents: a behavioral epidemiological analysis . Soc. Sci. Med. 56 ( 8 ), 1789 \u2013 1796 ( 2003 ).","journal-title":"Soc. Sci. Med."},{"issue":"1","key":"e_1_3_3_67_2","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1471-2458-6-66","article-title":"The impact of smoking on adherence to treatment for latent tuberculosis infection","volume":"6","author":"Lavigne M","year":"2006","unstructured":"Lavigne M , Rocher I , Steensma C The impact of smoking on adherence to treatment for latent tuberculosis infection . BMC Public Health 6 ( 1 ), 66 \u2013 69 ( 2006 ).","journal-title":"BMC Public Health"},{"issue":"1","key":"e_1_3_3_68_2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1164\/ajrccm.159.1.9807020","article-title":"A tuberculin screening and isoniazid preventive therapy program in an inner-city population","volume":"159","author":"Bock NN","year":"1999","unstructured":"Bock NN , Metzger BS , Tapia JR A tuberculin screening and isoniazid preventive therapy program in an inner-city population . Am. J. Respir. Crit. Care Med. 159 ( 1 ), 295 \u2013 300 ( 1999 ).","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"6","key":"e_1_3_3_69_2","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1164\/rccm.200510-1667OC","article-title":"Predicting non-completion of treatment for latent tuberculous infection","volume":"174","author":"Shieh FK","year":"2006","unstructured":"Shieh FK , Snyder G , Horsburgh CR Predicting non-completion of treatment for latent tuberculous infection . Am. J. Respir. Crit. Care Med. 174 ( 6 ), 717 \u2013 721 ( 2006 ).","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"e_1_3_3_70_2","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jinf.2006.04.010","article-title":"Predictors of failure to complete treatment for latent tuberculosis infection","volume":"54","author":"Parsyan AE","year":"2007","unstructured":"Parsyan AE , Saukkonen J , Barry MA Predictors of failure to complete treatment for latent tuberculosis infection . J. Infect. 54 ( 3 ), 262 \u2013 266 ( 2007 ).","journal-title":"J. Infect."},{"issue":"2","key":"e_1_3_3_71_2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1378\/chest.09-0394","article-title":"Latent TB infection treatment acceptance and completion in the United States and Canada","volume":"137","author":"Horsburgh CR","year":"2010","unstructured":"Horsburgh CR , Goldberg S , Bethel J Latent TB infection treatment acceptance and completion in the United States and Canada . Chest 137 ( 2 ), 401 \u2013 409 ( 2010 ).","journal-title":"Chest"},{"issue":"12","key":"e_1_3_3_72_2","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.5588\/ijtld.13.0423","article-title":"Cost\u2013effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States","volume":"17","author":"Shepardson D","year":"2013","unstructured":"Shepardson D , Marks SM , Chesson H Cost\u2013effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States . Int. J. Tuberc. Lung Dis. 17 ( 12 ), 1531 \u2013 1537 ( 2013 ).","journal-title":"Int. J. Tuberc. Lung Dis."},{"issue":"2","key":"e_1_3_3_73_2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.5588\/ijtld.11.0445","article-title":"Global isoniazid resistance patterns in rifampin-resistant and rifampin-susceptible tuberculosis","volume":"16","author":"Smith SE","year":"2012","unstructured":"Smith SE , Kurbatova EV , Cavanaugh JS Global isoniazid resistance patterns in rifampin-resistant and rifampin-susceptible tuberculosis . Int. J. Tuberc. Lung Dis. 16 ( 2 ), 203 \u2013 205 ( 2012 ).","journal-title":"Int. J. Tuberc. Lung Dis."},{"issue":"4","key":"e_1_3_3_74_2","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1002\/prot.21376","article-title":"A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910","volume":"67","author":"de Jonge MR","year":"2007","unstructured":"de Jonge MR , Koymans LHM , Guillemont JEG A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910 . Proteins 67 ( 4 ), 971 \u2013 980 ( 2007 ).","journal-title":"Proteins"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.2217\/cer.15.3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T12:35:58Z","timestamp":1679229358000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer.15.3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":72,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["10.2217\/cer.15.3"],"URL":"https:\/\/doi.org\/10.2217\/cer.15.3","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5]]}}}